Roche says Genentech divarasib beats sotorasib or adagrasib in Phase III NSCLC trial

  • Roche reported Phase III Krascendo 1 results showing its Genentech unit’s divarasib beat sotorasib or adagrasib in previously treated KRAS G12C NSCLC.
  • Trial met primary endpoint on progression-free survival, with a statistically significant overall survival benefit.
  • Safety profile stayed consistent with prior data, with treatment-related events described as manageable and reversible.
  • Data will be presented at an upcoming medical meeting, with regulatory submissions planned to support potential approvals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20260701637339) on July 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.